Luye Pharma Group Ltd. (FRA:LUP)

Market Cap	776.93M -52.5%
Revenue (ttm)	789.81M -0.6%
Net Income	89.73M +75.4%
EPS	0.02 +64.5%
Shares Out	n/a
PE Ratio	8.66
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.1920
Previous Close	0.1870
Day's Range	0.1920 - 0.1920
52-Week Range	0.1870 - 0.3960
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2026

About Luye Pharma Group

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema and edema caused by traum...

• Industry: Pharmaceutical Preparations
• Founded: 1994
• Employees: 5,221
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LUP

Financial Performance

In 2025, Luye Pharma Group's revenue was 6.31 billion, an increase of 4.07% compared to the previous year's 6.06 billion. Earnings were 618.75 million, an increase of 31.12%.

Financial numbers in CNY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 20, 2026

Data Sources Report a data error